BASF completes €270m sale of custom synthesis business to Siegfried Holding

Published: 1-Oct-2015
Finance Digital

Deal includes parts of BASF's active pharmaceutical ingredients business


BASF has sold its pharmaceutical custom synthesis business and parts of its active pharmaceutical ingredients (APIs) business to Siegfried Holding for €270m.

The sale was first announced in May and the relevant merger control approvals have now been granted.

From today, Siegfried Holding has taken over the operational management of the businesses and around 850 people have transferred to Siegfried.

The APIs sold to Siegfried include ephedrine, pseudoephedrine and caffeine.

Ibuprofen, omega-3 fatty acids and polyethylenglycol (PEG) will remain a key part of BASF’s portfolio.

  • Companies:
  • BASF Personal Care and Nutrition GmbH
See more

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Read more
Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community

Trending Articles

  1. TrakCel to support cell and gene therapy orchestration with OCELLOS IT solution The IT system allows cell and gene therapy (CGT) manufacturers to track the progress of personalised CGTs in real-time, while also managing their supply chain
  2. How AI can optimise your pharmaceutical manufacturing processes and raise throughput Artificial intelligence (AI) allows pharmaceutical manufacturers to perform predictive maintenance, which can reduce downtime and enhance process efficiency
  3. Ascend Advanced Therapies expands US footprint through Advanced BioScience Laboratories merger Ascend's collaboration with EW Healthcare partners will expand its reach in the US pharmaceutical market through capital investment and an uptick in GMP AAV manufacturing capacity
  4. Syncona launches early-stage drug development company, Slingshot Therapeutics The novel early-stage pharmaceutical company aims to collaborate with academic institutions to bring their findings to the clinic, with their first programme centring around inflammatory disease
  5. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Ingredients

Five key takeaways from LogiChem EU 2019

Having recently attended the LogiChem EU 2019 event in Amsterdam, the Netherlands, LLamasoft's Dr Madhav Durbha shares his insights from the chemical industry’s supply chain community
Manufacturing

BASF selects Emerson to enhance flexibility and production at German chemical plant

Emerson automation to improve operational efficiency and enhance cybersecurity for world’s largest chemical manufacturer
Manufacturing

BASF invests in carbon recycling company LanzaTech

The patented biotechnological procedure cuts carbon dioxide emissions by turning carbon monoxide and hydrogen into ethanol
Ingredients

Colorcon to purchase BASF’s Kollicoat IR coating system product line

The two firms will also further their cooperation to offer superior functional coatings for pharmaceutical tablets
Design & Build

Siegfried acquires three BASF sites

Acquisition represents the final step in Siegfried’s targeted 5-year procurement policy
Ingredients

BASF to sell custom synthesis and parts of pharma API business to Siegfried Holding

Ibuprofen, omega-3 fatty acids and polyethylenglycol will remain a key part of BASF’s portfolio
Finance

BASF to cut 260 jobs in Nutrition & Health division by 2015

Aims to strengthen profitability of its Performance Products segment
Subscribe now